Please login to the form below

Not currently logged in
Email:
Password:

KRAS mutation

This page shows the latest KRAS mutation news and features for those working in and with pharma, biotech and healthcare.

Amgen reveals more data on KRAS drug

Amgen reveals more data on KRAS drug

It is estimated that around 14% of NSCLC adenocarcinoma patients and roughly 5% of colorectal cancer patients have the KRAS G12C mutation. ... Amgen is leading the field among companies developing inhibitors of KRAS, an oncogene that is implicated in

Latest news

  • Boehringer bolsters KRAS push with $720m Lupin deal Boehringer bolsters KRAS push with $720m Lupin deal

    Once considered all-but ‘undruggable’, there are signs of progress in the KRAS field, with Amgen reporting encouraging anti-tumour activity with its  AMG 510 candidate – which targets a KRAS mutation ... the hope of providing “more effective and

  • Boehringer Ingelheim forms ‘virtual research’ alliance with MD Anderson Boehringer Ingelheim forms ‘virtual research’ alliance with MD Anderson

    Mutations in the KRAS pathway have been recognised for decades as a key part of oncology research. ... In June this year, Amgen reported safety, tolerability and preliminary anti-tumour activity in a phase 1 trial of a candidate which targets a KRAS

  • Has Amgen cracked KRAS? First clinical data says maybe Has Amgen cracked KRAS? First clinical data says maybe

    It is estimated that around 14% of NSCLC adenocarcinoma patients and roughly 5% of colorectal cancer patients have the KRAS G12C mutation. ... The KRAS G12C mutation has emerged as a clear front-runner among the various targets for pharmacological

  • So far so good for Amgen's much-anticipated KRAS inhibitor So far so good for Amgen's much-anticipated KRAS inhibitor

    The KRAS G12C mutation is present in approximately 14% of non-small cell lung adenocarcinomas and 5% of colorectal cancers, with a 1%-3% rate in other solid tumours. ... Amgen is in a race with Mirati Therapeutics to bring a KRAS G12C inhibitor through

  • AZ's selumetinib stumbles at last fence in lung cancer AZ's selumetinib stumbles at last fence in lung cancer

    NSCLC) whose tumours tested positive for the KRAS mutation in the SELECT-1 trial. ... KRAS is one of the most common mutations seen in NSCLC - occurring in around a third of patients - and typically causes adenocarcinoma tumours that are associated with

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics